Enveric Biosciences’ EVM301 portfolio receives five additional US patents: Cambridge, Massachusetts Wednesday, November 6, 2024, 17:00 Hrs [IST] Enveric Biosciences, a biotechno ...

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiatric disorders, today ...

Special Report: Clinical stage biotech Tryptamine Therapeutics has secured firm commitments from new and existing ...

The Company is investigating novel molecules within the CYB005 program at non-hallucinogenic doses for ... program reinforces our commitment to expanding the breadth of innovative development work ...

Cybin’s sector-leading intellectual property portfolio now includes over 70 granted patents and more than 220 patent applications pending – The Company is investigating novel molecules within the ...

Key Laboratory of Organic Synthesis of Jiangsu Province, College of Chemistry, Chemical Engineering and Materials Science & Collaborative Innovation Center of Suzhou Nano Science and Technology, ...

Special Report: Tryptamine Therapeutics has achieved a key milestone in development of its innovative IV-infused psilocin formulation TRP-8803, which was found to be generally safe and well ...

Tryptamine’s IV-infused psilocin formulation TRP-8803 found to be generally safe and well tolerated in a Phase 1b study. Special Report: Tryptamine Therapeutics has achieved a key milestone in ...

Sponsor Message We readers learn almost all of this information in the first pages of Clean, a slim, extraordinary novel by Chilean author, Alia Trabucco Zerán, translated into English by Sophie ...

By Dan Fesperman Dan Fesperman is the author of “Winter Work.” His 14th novel, “Pariah,” will be published next year. When you purchase an independently reviewed book through our site ...